References
- Agnihotri SA, Soppimath KS, Betageri GV. 2010. Controlled release application of multilamellar vesicles: a novel drug delivery approach. Drug Deliv 17:92–101.
- Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. 2002. Targeting to macrophages: role of physicochemical properties of particulate carriers – liposomes and microspheres – on the phagocytosis by macrophages. J Control Release 79:29–40.
- Alving CR. 1998. Macrophages as targets for delivery of liposome-encapsulated antimicrobial agents. Adv Drug Deliv Rev 2:107–128.
- Atkins PJ, Barker NP, Mathisen D. 1992. The design and development of inhalation drug delivery systems. In: Pharmaceutical Inhalation Aerosol Technology. Hickey AJ (Ed.). Marcel Dekker: New York, USA.
- Brain JD, Knudson DE, Sorokin SP, Davis MA. 1976. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. Environ Res 11:13–33.
- Castro RAE, Teresa MRM, Evora AOL, Feiteira JC, Silva MR, Beja AM, Canotilho J, Eusebio MES. 2010. A new insight into pyrazinamide polymorphic forms and their thermodynamic relationships. Cryst Growth Des 10:274–282.
- Changsan N, Chan HK, Separovic F, Srichana T. 2009a. Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation. J Pharm Sci 98:628–639.
- Changsan N, Nilkaeo A, Pungrassami P, Srichana T. 2009b. Monitoring safety of liposomes containing rifampicin on respiratory cell lines and in vitro efficacy against Mycobacterium bovis in alveolar macrophages. J Drug Target 17:751–762.
- Crowder TM, Rosati JA, Schroeter JD, Hickey AJ, Martonen TB. 2002. Fundamental effects of particle morphology on lung delivery: predictions of Stokes’ law and the particular relevance to dry powder inhaler formulation and development. Pharm Res 19:239–245.
- Elhissi AM, Faizi M, Naji WF, Gill HS, Taylor KM. 2007. Physical stability and aerosol properties of liposomes delivered using an air-jet nebulizer and a novel micropump device with large mesh apertures. Int J Pharm 334:62–70.
- Elhissi AMA, Islam MA, Arafat B, Taylor M, Ahmed W. 2010. Development and characterisation of freeze-dried liposomes containing two anti-asthma drugs. Micro & Nano Letters 5:184–188.
- Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP. 2003. Physico-chemical stability of colloidal lipid particles. Biomaterials 24:4283–4300.
- Thompson DC. 1992. Pharmacology of therapeutic aerosols. In: Pharmaceutical Inhalation Aerosol Technology. Hickey AJ (Ed.). Marcel Dekker: New York, USA.
- Huttunen K, Ruotsalainen M, Iivanainen E, Torkko P, Katila M, Hirvonen M. 2000. Inflammatory responses in RAW264.7 macrophages caused by mycobacteria isolated from moldy houses. Environ Toxicol Pharmacol 8:237–244.
- Johnston DE. 1999. Special considerations in interpreting liver function tests. Am Fam Physician 59:2223–2230.
- Kanchan V, Panda AK. 2007. Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials 28:5344–5357.
- Khuller GK, Kapur M, Sharma S. 2004. Liposome technology for drug delivery against mycobacterial infections. Curr Pharm Des 10:3263–3274.
- Mitchison DA, Fourie PB. 2010. The near future: improving the activity of rifamycins and pyrazinamide. Tuberculosis (Edinb) 90:177–181.
- Morris KR, Rodriguez-Hornedo N. 1993. Hydrates. In: Encyclopedia of Pharmaceutical Technology. Swarbrick J, Boylan JC (Eds.). Marcel Dekker: New York, USA. 393–440.
- Nolan LM, Tajber L, McDonald BF, Barham AS, Corrigan OI, Healy AM. 2009. Excipient-free nanoporous microparticles of budesonide for pulmonary delivery. Eur J Pharm Sci 37:593–602.
- Pandey R, Sharma S, Khuller GK. 2004. Nebulization of liposome encapsulated antitubercular drugs in guinea pigs. Int J Antimicrob Agents 24:93–94.
- Punturee K, Wild CP, Vinitketkumneun U. 2004. Thai medicinal plants modulate nitric oxide and tumor necrosis factor-alpha in J774.2 mouse macrophages. J Ethnopharmacol 95:183–189.
- Rojanarat W, Changsan N, Tawithong E, Pinsuwan S, Chan HK, Srichana T. 2011. Isoniazid proliposome powders for inhalation-preparation, characterization and cell culture studies. Int J Mol Sci 12:4414–4434.
- Ross PD, Rekharsky MV. 1996. Thermodynamics of hydrogen bond and hydrophobic interactions in cyclodextrin complexes. Biophys J 71:2144–2154.
- Saetern AM, Flaten GE, Brandl M. 2004. A method to determine the incorporation capacity of camptothecin in liposomes. AAPS PharmSciTech [Online] 5:1–8. http://www.aapspharmscitech.org. Accessed on 14 September 2010.
- Salfinger M, Heifets LB. 1988. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob Agents Chemother 32:1002–1004.
- Sharp PE, LaRegina MC. 1998. The laboratory rat. In: The Laboratory Animal Pocket Reference Series. Suckow MA (Ed.). CRC Press LLC: Florida, USA. 17.
- Srichana T, Suedee R, Srisudjai P. 2003. Application of spectrofluorometry for evaluation of dry powder inhalers in vitro. Pharmazie 58:125–129.
- Taylor K, Elhissi A. 2006. Preparation of liposomes for pulmonary delivery using medical nebulizers. In: Liposome Technology. Kevin M, Tayler G, Abdelbary M, Elhissi A (Eds.). Informa Healthcare: London, England. 67–84.
- USP 30 and NF 25; USP-NF. 2007. Guideline No. 905: Uniformity of dosage units. In: US Pharmacopeia 30-NF 25. US Pharmacopeial Convention (ed.). US Pharmacopeial Convention, Inc.: Rockville, USA. 378–384.
- Wagner A, Vorauer-Uhl K. 2011. Liposome technology for industrial purposes. J Drug Deliver. doi:10.1155/2011/591325. http://www.hindawi.com. Accessed on 11 July 2011.